DZ2002 is primarily utilized in the field of biomedical research due to its role as a reversible S-adenosyl-L-homocysteine hydrolase (SAHH) inhibitor. Its application is significant in studying autoimmune diseases, as it helps modulate immune responses by regulating methylation processes. This compound has shown potential in reducing inflammation and suppressing autoimmune reactions, making it a valuable tool in experimental therapies for conditions like lupus and rheumatoid arthritis. Additionally, DZ2002 is being explored for its anti-fibrotic properties, particularly in treating liver fibrosis, where it aids in preventing excessive tissue scarring. Its ability to influence cellular signaling pathways also makes it a candidate for cancer research, particularly in understanding tumor growth and metastasis. Overall, DZ2002 serves as a promising compound in developing treatments for complex diseases.